Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1288379 | 0.91 | CYP17A1 (0.41) | CYP17A1NAMPTCNR2KDM6BKDM4C | |
| SCHEMBL6624548 | 0.83 | CNR2 (0.46) | CNR2METAP1 | |
| SCHEMBL23674773 | 0.77 | CYP17A1 (0.48) | CYP17A1NAMPTRAB9ABRS3METAP1 | |
| SCHEMBL18522430 | 0.76 | NAMPT (0.50) | CYP17A1NAMPTKDM4CRAB9ABRS3 | |
| SCHEMBL22498554 | 0.76 | NAMPT (0.44) | CYP17A1NAMPT | |
| SCHEMBL6515388 | 0.75 | CYP17A1 (0.40) | CYP17A1NAMPTCNR2KDM6BKDM4C | |
| SCHEMBL536056 | 0.75 | NOD2 (0.50) | CYP17A1NAMPTRAB9AMETAP1 | |
| SCHEMBL31707395 | 0.75 | NOD2 (0.50) | CYP17A1NAMPTRAB9AMETAP1 | |
| SCHEMBL5746768 | 0.75 | CYP17A1 (0.46) | CYP17A1NAMPTKDM6BKDM4CRAB9A | |
| SCHEMBL31437242 | 0.74 | KDM6B (0.41) | CNR2KDM6BKDM4CRAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091200-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX U.S.A. LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-6900220-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | BECKER CYRUS K (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1363899-B1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-05-11 | — | — | EP | disclosed |
| EP-1363899-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2002053558-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMAN-LA ROCHE AG (CH) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | CYP17A1 418/4885NAMPT 3334/4885CNR2 48/4885 |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | CYP17A1 425/4885NAMPT 3354/4885CNR2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.